LLY

1,021.91

+0.56%↑

JNJ

246.57

+0.8%↑

ABBV

224.27

-1.67%↓

NVS

163.68

-1.12%↓

MRK

122.02

+0.62%↑

LLY

1,021.91

+0.56%↑

JNJ

246.57

+0.8%↑

ABBV

224.27

-1.67%↓

NVS

163.68

-1.12%↓

MRK

122.02

+0.62%↑

LLY

1,021.91

+0.56%↑

JNJ

246.57

+0.8%↑

ABBV

224.27

-1.67%↓

NVS

163.68

-1.12%↓

MRK

122.02

+0.62%↑

LLY

1,021.91

+0.56%↑

JNJ

246.57

+0.8%↑

ABBV

224.27

-1.67%↓

NVS

163.68

-1.12%↓

MRK

122.02

+0.62%↑

LLY

1,021.91

+0.56%↑

JNJ

246.57

+0.8%↑

ABBV

224.27

-1.67%↓

NVS

163.68

-1.12%↓

MRK

122.02

+0.62%↑

Search

Quanterix Corp

Deschisă

SectorSănătate

5.94 2.59

Rezumat

Modificarea prețului

24h

Curent

Minim

5.63

Maxim

5.93

Indicatori cheie

By Trading Economics

Venit

-3.5M

-34M

Vânzări

16M

40M

Marjă de profit

-83.479

Angajați

471

EBITDA

5.7M

-31M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+29.31% upside

Dividende

By Dow Jones

Următoarele câștiguri

16 mar. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

30M

268M

Deschiderea anterioară

3.35

Închiderea anterioară

5.94

Sentimentul știrilor

By Acuity

50%

50%

165 / 351 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Quanterix Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 feb. 2026, 22:31 UTC

Câștiguri

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18 feb. 2026, 22:18 UTC

Câștiguri

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18 feb. 2026, 22:11 UTC

Câștiguri

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18 feb. 2026, 21:52 UTC

Câștiguri

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18 feb. 2026, 23:56 UTC

Market Talk

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18 feb. 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 feb. 2026, 23:46 UTC

Market Talk

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18 feb. 2026, 23:34 UTC

Market Talk
Câștiguri

Brambles' Cost Control Stands Out to Bull -- Market Talk

18 feb. 2026, 23:33 UTC

Market Talk

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18 feb. 2026, 23:32 UTC

Market Talk

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18 feb. 2026, 22:45 UTC

Câștiguri

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18 feb. 2026, 22:44 UTC

Market Talk

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18 feb. 2026, 22:37 UTC

Câștiguri

Nutrien 4Q EPS $1.18 >NTR.T

18 feb. 2026, 22:37 UTC

Câștiguri

Nutrien 4Q Sales $5.34B >NTR.T

18 feb. 2026, 22:35 UTC

Câștiguri

Pan American Silver 4Q EPS $1.07 >PAAS

18 feb. 2026, 22:35 UTC

Câștiguri

Pan American Silver 4Q Rev $1.18B >PAAS

18 feb. 2026, 22:30 UTC

Câștiguri

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18 feb. 2026, 22:29 UTC

Câștiguri

Kinross Gold 4Q EPS 75c >K.T

18 feb. 2026, 22:22 UTC

Câștiguri

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18 feb. 2026, 22:22 UTC

Market Talk

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18 feb. 2026, 22:16 UTC

Câștiguri

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18 feb. 2026, 22:05 UTC

Câștiguri

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18 feb. 2026, 22:03 UTC

Câștiguri

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18 feb. 2026, 22:02 UTC

Câștiguri

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18 feb. 2026, 22:02 UTC

Câștiguri

Kaiser Aluminum 4Q Sales $929M >KALU

18 feb. 2026, 22:02 UTC

Câștiguri

Kaiser Aluminum 4Q EPS $1.68 >KALU

18 feb. 2026, 22:00 UTC

Câștiguri

Kinross Gold 4Q Adj EPS 67c >KGC

18 feb. 2026, 22:00 UTC

Câștiguri

Kinross Gold 4Q Sales $2.02B >KGC

18 feb. 2026, 21:56 UTC

Câștiguri

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18 feb. 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

Comparație

Modificare preț

Quanterix Corp Așteptări

Obiectiv de preț

By TipRanks

29.31% sus

Prognoză pe 12 luni

Medie 7.5 USD  29.31%

Maxim 8 USD

Minim 7 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruQuanterix Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

2 ratings

0

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

5.34 / 6.015Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Bullish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

165 / 351 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
help-icon Live chat